Empowering laboratories to deliver inclusive diagnostics

The Indian healthcare sector is growing rapidly with significant opportunities in the diagnostic sector. Driven by trends such as newer tests that address critical and precise clinical needs and rising per-capita income, the sector is projected to grow at a CAGR of 14% to $20 bn by FY 2026.

Growing demand for specialized tests
Specialized tests, such as PCR and genomic testing, which comprise 15-22% by volume and 40-45% by value of the Indian diagnostic market, are driving market growth. From oncology, infectious diseases, cardiovascular conditions and neurodegenerative disorders, specialty diagnostics offer critical insights that enable precise diagnosis and tailored treatment decisions.

Laboratories across the country now have access to molecular diagnostics and Next Generation Sequencing (NGS) unlocking an immense potential to enhance clinical decision-making, treatment planning, and monitoring of patients.

Molecular pathology testing is poised to grow at an impressive rate of 35-40% year-on-year. Molecular diagnosis allows for high-throughput sequencing of DNA or RNA, enabling the detection of mutations, and identification of pathogens with accuracy and sensitivity. NGS enables the identification of genetic alterations, leading to informed personalized treatment plans and improved patient outcomes. For example, in cancer diagnostics, NGS can detect mutations in oncogenes, tumor suppressor genes, and other cancer-associated genes, guiding the selection of appropriate targeted therapies. The convergence of NGS with digital technology has emerged as a game-changer in diagnostics, disease prevention, and treatment, heralding a paradigm shift in the field.

Precision medicine is transforming the landscape of healthcare, offering tailored solutions to revolutionize patient care and improve health outcomes.

Combatting Antimicrobial Resistance (AMR)
Often labeled as the ‘silent pandemic’, AMR has been gaining increased prominence over the past few years. In India, prevalence of communicable diseases, an overburdened public health system, limited laboratory capacity for etiology-based diagnosis and appropriately targeted treatment have reduced the focus on AMR prevention. Drug susceptibility tests to test bacteria for sensitivity to drugs or to detect resistance patterns, should be deployed to help fight AMR even in low-resource settings.

Thermo Fisher Scientific offers end-to-end solutions
At Thermo Fisher Scientific, we are committed to providing reliable instruments, solutions, services and support to meet the needs of diagnostic laboratories.

Our comprehensive range of instruments, an expanding menu of optimized assays, analysis and reporting software solutions and validation services accelerate the routine analysis of clinical research samples.

With an extensive range of assays and reagents optimized for use on our genetic analysis platforms, we offer sample-to-answer qualified solutions for a variety of areas in precision medicine.

Our laboratory equipment portfolio includes a complete range of centrifuges, biosafety cabinets, CO2 incubators, and the most comprehensive range of cold storage solutions ranging from 4°C laboratory refrigerator to -196°C cryogenic storage.

Recently, Thermo Fisher Scientific India launched the ‘Made in India’ TSV series refrigerators and freezers, an ideal solution for mid to long-term storage of non-critical samples in academic research and clinical settings.

Our laboratory consumables are designed to improve the accuracy, efficiency, and productivity of scientific research and testing.

Every day we look for opportunities to collaborate to help solve some of the world’s greatest health challenges. We take pride in our Mission, to enable our customers to make the world healthier, cleaner and safer.